Physician profile
Misha Max Heller
NPI 1568717221
$9,715.33
in general payments reported to CMS, 2019-2025
30 companies · $1,799 in 2025
The $1,799 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $864 · 2021: $1,062 · 2022: $841 · 2023: $1,941 · 2024: $2,761 · 2025: $1,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,278 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,278.08 |
| Education | $222.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,364.27 | 2019-2025 | |
| Amgen INC. | $1,687.12 | 2020-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $1,086.96 | 2021-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $721.56 | 2022-2025 | |
| Lilly USA, LLC | $393.66 | 2021-2025 | Taltz, Ebglyss, Zepbound |
| Ucb, INC. | $353.04 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $349.63 | 2022-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $287.48 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $269.25 | 2022-2024 | Vtama |
| Pfizer INC. | $268.21 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $222.60 | 2019-2025 | |
| Galderma Laboratories, L.P. | $215.33 | 2020-2025 | Nemluvio |
| Merz North America, INC. | $180.52 | 2020 | |
| Almirall LLC | $177.03 | 2020-2025 | Seysara |
| Incyte Corporation | $168.78 | 2021-2024 | Opzelura |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $168.23 | 2023-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $131.47 | 2020-2022 | |
| Celgene Corporation | $129.29 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $104.17 | 2023-2024 | Sotyktu |
| Genentech USA, INC. | $86.94 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $70.44 | 2020-2021 | |
| Journey Medical Corporation | $49.55 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.11 | 2022-2023 | Spevigo |
| Dusa Pharmaceuticals, INC. | $37.87 | 2019 | |
| Dermira, INC. | $37.60 | 2019-2020 | |
| Glenmark Therapeutics INC. | $37.00 | 2019 | |
| Verrica Pharmaceuticals INC. | $22.41 | 2024 | Ycanth |
| Revance Therapeutics, INC. | $19.86 | 2024 | Daxxify |
| Paratek Pharmaceuticals, INC. | $18.55 | 2025 | Nuzyra |
| Organon LLC | $14.40 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misha Heller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.